Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is a clinical-stage oncology company focused on the development and potential commercialization of azenosertib, an investigational, potentially first-in-class, selective, orally bioavailable WEE1 kinase inhibitor. The company's primary focus is on treating Cyclin E1-positive platinum-resistant ovarian cancer (PROC), a biomarker-defined population comprising approximately 50% of PROC patients who currently have no specifically targeted treatment options. Zentalis is advancing azenosertib through multiple clinical programs: the registration-intended DENALI Phase 2 trial designed to support accelerated FDA approval, the confirmatory ASPENOVA Phase 3 randomized trial designed to support full approval in the U.S. and major ex-U.S. markets, and the MUIR Phase 1b combination trial exploring azenosertib with chemotherapy backbones and bevacizumab in platinum-sensitive ovarian cancer maintenance settings. The company has developed a proprietary immunohistochemistry-based companion diagnostic to identify Cyclin E1-positive patients and is pursuing franchise expansion into earlier lines of ovarian cancer therapy and additional tumor types including triple-negative breast cancer. Zentalis is pre-revenue and trades on the Nasdaq under the ticker ZNTL. Updated Aug 6, 2026